GC376
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
|
GC376 is a broad-spectrum antiviral medication under development by the biopharmaceutical company Anivive Lifesciences for therapeutic uses in humans and animals.[1] Anivive licensed the exclusive worldwide patent rights to GC376 from Kansas State University.[2] As of 2020, GC376 is being investigated as treatment for COVID-19.[3] GC376 shows activity against many human and animal viruses including coronavirus and norovirus;[4] the most extensive research has been multiple in vivo studies in cats treating a coronavirus which causes deadly feline infectious peritonitis.[5] Other research supports use in porcine epidemic diarrhea virus.[6]
COVID-19
Since GC376 shows broad-spectrum activity against coronavirus,
Pharmacology
Pharmacodynamics
GC376 is a
See also
References
- ^ "Anivive". www.anivive.com. Retrieved 2020-05-14.
- ^ "Anivive licenses antiviral drug for fatal cat disease". www.k-state.edu. September 20, 2018. Retrieved 2020-05-14.
- ^ Stockwell B (6 May 2020). "COVID-19 Virtual Symposium". Retrieved 2020-05-14 – via YouTube.
- PMID 24055466.
- PMID 28901812.
- ^ PMID 32098094.
- PMID 32006468.
- PMID 32022370.
- S2CID 216145410.
- S2CID 218551888.